Literature DB >> 26782575

Meta-analysis of association between IL-6 -634C/G polymorphism and osteoporosis.

L Yan1, R Hu1, S Tu1, W J Cheng1, Q Zheng1, J W Wang1, W S Kan1, Y J Ren1.   

Abstract

Osteoporosis is a common disease in the aging population and studies have shown that interleukin-6 (IL-6) is potentially implicated in its pathogenesis. This study was designed to assess the association between the IL-6 gene -634C/G polymorphism and osteoporosis. PubMed, Embase, China National Knowledge Infrastructure, and Wanfang databases were searched for eligible studies published up to and including December 2014 in English or Chinese. Meta-analysis was conducted by the RevMan5.2 software. Weighted mean difference and 95% confidence interval (95%CI) were calculated by a fixed-effect or random-effect model. Bone mineral density (BMD) was regarded as the assessment index. As a result, a total of four articles with 3068 subjects were included. Differences in BMD between the CC and GG genotypes were 0.03 g/cm(2) (95%CI = 0.01 to 0.05) at total body, 0.01 g/cm(2) (95%CI = 0.00 to 0.03) at femoral neck, and 0.03 g/cm(2) (95%CI = 0.00 to 0.06) at the lumbar spine (P < 0.05). For the CG versus GG genotypes, the differences in BMD were 0.03 g/cm(2) (95%CI = 0.02 to 0.05) at total body and 0.02 g/cm(2) (95%CI = 0.00 to 0.03 at the femoral neck (P < 0.05). For the CC versus CG genotypes, the differences in BMD were not significant (P > 0.05). In conclusion, the GG genotype of the -634C/G polymorphism in IL-6 appears to play a role in reducing BMD, which affects normal bone metabolism and leads to osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26782575     DOI: 10.4238/2015.December.29.32

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  8 in total

Review 1.  New Therapeutic Approaches and Biomarkers for Increased Healthspan.

Authors:  Paul C Guest
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Network pharmacology explores the mechanisms of Eucommia ulmoides cortex against postmenopausal osteoporosis.

Authors:  Yan Shao; Song Chen; Ke Zhou; Kaifeng Gan; Jin Li; Chenjie Xia
Journal:  Medicine (Baltimore)       Date:  2022-05-13       Impact factor: 1.817

3.  The association among 14-3-3η protein, inflammation, bone remodeling and osteoporosis in patients with rheumatoid arthritis.

Authors:  Yi Sun; Liang Hong; Changbai Gao
Journal:  Pak J Med Sci       Date:  2020 Jul-Aug       Impact factor: 1.088

4.  Interleukin-6 polymorphisms and risk of coronary artery diseases in a Chinese population: A case-control study.

Authors:  Yao Hongmei; Jia Yongping; Lv Jiyuan
Journal:  Pak J Med Sci       Date:  2016 Jul-Aug       Impact factor: 1.088

5.  Association between interleukin-6/6R gene polymorphisms and coronary artery disease in Russian population: influence of interleukin-6/6R gene polymorphisms on inflammatory markers.

Authors:  Vadim Mitrokhin; Alexey Nikitin; Olga Brovkina; Dmitry Khodyrev; Alexander Zotov; Nikita Vachrushev; Dmitry Dragunov; Andrey Shim; Mitko Mladenov; Andre Kamkin
Journal:  J Inflamm Res       Date:  2017-10-03

6.  No Interaction Effect between Interleukin-6 Polymorphisms and Acid Ash Diet with Bone Resorption Marker in Postmenopausal Women.

Authors:  Sook Yee Lim; Yoke Mun Chan; Vasudevan Ramachandran; Zalilah Mohd Shariff; Yit Siew Chin; Manohar Arumugam
Journal:  Int J Environ Res Public Health       Date:  2021-01-19       Impact factor: 3.390

7.  Osteomuscular symptoms on motorcycles in the city of Rio Branco, Acre, Brazil, West Amazon.

Authors:  Narjara Campos de Araújo; Orivaldo Florêncio de Souza; Mauro José de Deus Morais; Francisco Naildo Cardoso Leitão; Italla Maria Pinheiro Bezerra; Luiz Carlos de Abreu; Luciano Miller Reis Rodrigues
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

Review 8.  Cytokines in Inflammatory Disease.

Authors:  Shinwan Kany; Jan Tilmann Vollrath; Borna Relja
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.